Health ❯ Healthcare ❯ Drug Development

Clinical Trials

FDA Approval Regulatory Approval Real-World Evidence Side Effects Phase 2 Trials Eli Lilly Alzheimer's Disease Leqembi Biosimilar Approval Process Tumor-Infiltrating Lymphocytes

AstraZeneca’s COPD Antibody Tozorakimab Succeeds in Two Phase 3 Trials

The IL-33 drug cut COPD flare-ups, hinting at a new class.

EU Drug Panel Backs Imdylltra for Relapsed Small Cell Lung Cancer

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

FDA Warns Novo Nordisk Over Missed Reporting of Serious Semaglutide and GLP-1 Adverse Events

Perceptive Advisors Makes Praxis Its Largest Holding After Disclosing Big Q4 Buy

FDA Sets Single-Study Default for New Drug Approvals

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

TG Therapeutics Lifts 2026 Outlook After Strong Briumvi Year, Shares Jump

BioMarin to Acquire Amicus for $4.8 Billion in Cash

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Study Finds CBD–THC Combination Kills Ovarian Cancer Cells in Lab

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Roche Says Breast Cancer Pill Cuts Recurrence in Phase 3 Adjuvant Trial

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Tops Q3 Forecasts, Raises Profit Outlook

New Studies Recast Superbug Strategy With Targeted Cefiderocol Use and a Potent Rediscovered Antibiotic Lead

Health Canada Conditionally Authorizes First Alzheimer’s Drug to Slow Early Decline

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share